Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 and 33 of SEBI LODR Regulations
Audit Opinion:
Limited Review Report issued by Walker Chandiok & Co LLP with unmodified conclusion. No qualifications or modifications noted. The review report states: "nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement."
Key Financial Highlights [Amount in ₹ lacs]:
Standalone Results:
Revenue from Operations: ₹22,440.48 lacs (compared to ₹21,555.07 lacs in Q4 FY26 and ₹17,428.59 lacs in Q1 FY25)
Total Income: ₹23,841.99 lacs
Net Profit: ₹6,569.18 lacs
EPS: ₹5.28 (Basic and Diluted)
Other Equity: Not specified for current quarter
Consolidated Results:
Revenue from Operations: ₹22,440.48 lacs (compared to ₹21,555.32 lacs in Q4 FY26 and ₹17,428.59 lacs in Q1 FY25)
Total Income: ₹23,873.13 lacs
Net Profit: ₹6,589.01 lacs (Attributable to owners: ₹6,594.54 lacs, Non-controlling interests: ₹(5.53) lacs)
EPS: ₹5.30 (Basic), ₹5.29 (Diluted)
Other Equity: ₹44,221.87 lacs (as of March 31, 2026)
Segment-wise Performance:
Ayurvedic products/medicines: Revenue ₹11,828.31 lacs, Segment Result ₹4,124.11 lacs
Ayurvedic healthcare services: Revenue ₹10,474.66 lacs, Segment Result ₹4,271.13 lacs
Others: Revenue ₹137.51 lacs, Segment Result ₹137.51 lacs
Corporate Actions:
Dividend: Board recommended final dividend of ₹4.50 per equity share for year ended March 31, 2026, subject to shareholder approval at forthcoming AGM
Other Significant Information:
Asset Sale: Board approved sale of Derabassi hospital facility to M/s VSB Enterprises for ₹9.05 crore, expected completion in Q2 FY27. Derabassi hospital contributes 6-8% of total revenue. Company intends to continue operations from same premises under lease arrangement.
Subsidiary Operations: Jeena Sikho International LLC entered Share Purchase Agreement to acquire 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC (UAE) for total consideration of approximately ₹1,940.43 lacs. Share transfer pending regulatory formalities. Profit share of ₹0.53 crore booked in Q1 FY26 consolidated results.
Auditor Change: Previous auditor was KRA & Co. Chartered Accountants (review report dated August 14, 2025). Current auditor is Walker Chandiok & Co LLP.